Cardiac myofibroblasts participate in post-myocardial infarct (MI) wound healing, infarct scar formation, and remodeling of the ventricle remote to the site of infarction. The role of intracellular calcium handling in cardiac myofibroblasts as a modulator of cellular motility, contractile responses, and proliferation is largely unexplored. We have investigated the role of sodium calcium exchange (Na Ca exchange or NCX1.1) and non-selective cation channels (NSCCs) in regulation of myofibroblast function using a pharmacological inhibitor approach in vitro. Primary myofibroblasts were stimulated with PDGF-BB and cellular chemotaxis, contraction and proliferative responses were characterized using standard bioassays (Costar Transwell apparatuses, pre-formed collagen type I gel deformation assays, and 3H-thymidine incorporation). Stimulated cellular responses were compared to those in the presence of AG1296 (PDGFβR inhibitor), KB-R7943 (NCX inhibitor), gadolinium, nifedipine or ML-7. Immunofluorescence was used to determine localized expression of αSMA, SMemb, NCX1.1, and Cav1.2a in cultured myofibroblasts. Motility of myofibroblasts in the presence of PDGF-BB was blocked with AG1296 treatment. Immunoblotting and immunocytochemical studies revealed expression of NCX1.1 in fibroblasts and myofibroblasts. Motility (in the presence of either PDGF-BB or CT-1), contraction (in the presence of either PDGF-BB or TGFβ1), and proliferation (in the presence of PDGF-BB) were sensitive to KB-R7943 treatment of cells (7.5 and 10 μM for motility, 5 and 10 μM for contractility, and 10 μM for proliferation). Proliferation (in the presence of PDGF-BB), and contractility (in the presence of either PDGF-BB or TGFβ1) but not motility (in the presence of PDGF-BB) are sensitive to nifedipine treatment, while gadolinium treatment was associated only with decreased motility of cells (in the presence of either PDGF-BB, CT-1, or LoFGF-2). We found that ML-7 treatment inhibited cellular chemotaxis, and contraction. Thus cellular chemotaxis, contractile, and proliferation responses were sensitive to different pharmacologic treatment. Regulation of transplasmalemmal calcium movements may be important in cytokine and growth factor receptor-mediated cardiac myofibroblast motility, contractility, and proliferation. Furthermore, our results support the hypothesis that activation of specific calcium transport proteins is an important determinant of physiologic responses. / May 2006

Cardiac myofibroblasts participate in post-myocardial infarct (MI) wound healing, infarct scar formation, and remodeling of the ventricle remote to the site of infarction. The role of intracellular calcium handling in cardiac myofibroblasts as a modulator of cellular motility, contractile responses, and proliferation is largely unexplored. We have investigated the role of sodium calcium exchange (Na Ca exchange or NCX1.1) and non-selective cation channels (NSCCs) in regulation of myofibroblast function using a pharmacological inhibitor approach in vitro. Primary myofibroblasts were stimulated with PDGF-BB and cellular chemotaxis, contraction and proliferative responses were characterized using standard bioassays (Costar Transwell apparatuses, pre-formed collagen type I gel deformation assays, and 3H-thymidine incorporation). Stimulated cellular responses were compared to those in the presence of AG1296 (PDGFβR inhibitor), KB-R7943 (NCX inhibitor), gadolinium, nifedipine or ML-7. Immunofluorescence was used to determine localized expression of αSMA, SMemb, NCX1.1, and Cav1.2a in cultured myofibroblasts. Motility of myofibroblasts in the presence of PDGF-BB was blocked with AG1296 treatment. Immunoblotting and immunocytochemical studies revealed expression of NCX1.1 in fibroblasts and myofibroblasts. Motility (in the presence of either PDGF-BB or CT-1), contraction (in the presence of either PDGF-BB or TGFβ1), and proliferation (in the presence of PDGF-BB) were sensitive to KB-R7943 treatment of cells (7.5 and 10 μM for motility, 5 and 10 μM for contractility, and 10 μM for proliferation). Proliferation (in the presence of PDGF-BB), and contractility (in the presence of either PDGF-BB or TGFβ1) but not motility (in the presence of PDGF-BB) are sensitive to nifedipine treatment, while gadolinium treatment was associated only with decreased motility of cells (in the presence of either PDGF-BB, CT-1, or LoFGF-2). We found that ML-7 treatment inhibited cellular chemotaxis, and contraction. Thus cellular chemotaxis, contractile, and proliferation responses were sensitive to different pharmacologic treatment. Regulation of transplasmalemmal calcium movements may be important in cytokine and growth factor receptor-mediated cardiac myofibroblast motility, contractility, and proliferation. Furthermore, our results support the hypothesis that activation of specific calcium transport proteins is an important determinant of physiologic responses.

Cardiac myofibroblasts participate in post-myocardial infarct (MI) wound healing, infarct scar formation, and remodeling of the ventricle remote to the site of infarction. The role of intracellular calcium handling in cardiac myofibroblasts as a modulator of cellular motility, contractile responses, and proliferation is largely unexplored. We have investigated the role of sodium calcium exchange (Na Ca exchange or NCX1.1) and non-selective cation channels (NSCCs) in regulation of myofibroblast function using a pharmacological inhibitor approach in vitro. Primary myofibroblasts were stimulated with PDGF-BB and cellular chemotaxis, contraction and proliferative responses were characterized using standard bioassays (Costar Transwell apparatuses, pre-formed collagen type I gel deformation assays, and 3H-thymidine incorporation). Stimulated cellular responses were compared to those in the presence of AG1296 (PDGFβR inhibitor), KB-R7943 (NCX inhibitor), gadolinium, nifedipine or ML-7. Immunofluorescence was used to determine localized expression of αSMA, SMemb, NCX1.1, and Cav1.2a in cultured myofibroblasts. Motility of myofibroblasts in the presence of PDGF-BB was blocked with AG1296 treatment. Immunoblotting and immunocytochemical studies revealed expression of NCX1.1 in fibroblasts and myofibroblasts. Motility (in the presence of either PDGF-BB or CT-1), contraction (in the presence of either PDGF-BB or TGFβ1), and proliferation (in the presence of PDGF-BB) were sensitive to KB-R7943 treatment of cells (7.5 and 10 μM for motility, 5 and 10 μM for contractility, and 10 μM for proliferation). Proliferation (in the presence of PDGF-BB), and contractility (in the presence of either PDGF-BB or TGFβ1) but not motility (in the presence of PDGF-BB) are sensitive to nifedipine treatment, while gadolinium treatment was associated only with decreased motility of cells (in the presence of either PDGF-BB, CT-1, or LoFGF-2). We found that ML-7 treatment inhibited cellular chemotaxis, and contraction. Thus cellular chemotaxis, contractile, and proliferation responses were sensitive to different pharmacologic treatment. Regulation of transplasmalemmal calcium movements may be important in cytokine and growth factor receptor-mediated cardiac myofibroblast motility, contractility, and proliferation. Furthermore, our results support the hypothesis that activation of specific calcium transport proteins is an important determinant of physiologic responses.

No description available.

La stéatohépatite non alcoolique (NASH) est une pathologie du foie dont l’amplitude et les répercussions sont de plus en plus préoccupantes dans le monde médical ou biomédical. Elle est associée à l’obésité, au syndrome métabolique et au diabète sucré de type II. La recherche de la thérapie optimale pour le NASH est un domaine en plein essor puisqu’aucun traitement n’est suffisamment efficace à ce jour. La présente étude fait le point sur de nouvelles possibilités de traitements qui se sont avérés efficaces pour contrer les différentes lésions métaboliques et cellulaires rencontrées dans un modèle in vivo chez le rat où le NASH est induit par l’ingestion d’une diète riche en gras. Cette étude démontre, tout d’abord, que les traitements durant six semaines avec l’acide ursodéoxycholique (UDCA) et son dérivé le NCX 1000, possédant des propriétés donatrices de monoxyde d’azote, à doses équimolaires, protègent de manière équivalente le foie contre le stress oxydatif, l’hyperinsulinémie, l’inflammation et la fibrose causés par la stéatohépatite. De plus, la combinaison d’une plus faible dose de NCX 1000 avec un antioxydant lipophile tel que la vitamine E offre une protection similaire, particulièrement au niveau des paramètres du stress oxydatif. Par ailleurs, l’étude illustre aussi que la silibinine, composé polyphénolique actif du chardon marie (Silybum marianum) et utilisé en traitement pendant 5 semaines, possède un pouvoir hépatoprotecteur, des propriétés antioxydantes et un effet hypoinsulinémique dans ce modèle de stéatohépatite d’origine nutritionnelle. Le potentiel thérapeutique de ces composés en fait des candidats de choix pour le traitement du NASH qui méritent de faire l’objet d’études cliniques poussées. / Nonalcoholic steatohepatitis (NASH) is a serious liver condition related to the metabolic syndrome, obesity, and type II diabetes mellitus whose prevalence is drastically rising in developed countries and worldwide. Several remedies were investigated for the treatment of NASH but an efficient therapy has yet to be developed. In the present study, we explored novel therapeutic possibilities that were thought to be effective for the treatment of experimental high-fat diet-induced NASH the in rat. Our results show that a chronic six week treatment with a high dose of NCX 1000, a derivative of ursodeoxycholic acid (UDCA) with nitric oxide (NO) donating properties, is efficient at reversing steatosis, oxidative stress, inflammation, insulin resistance and fibrosis; major hallmarks of experimental NASH. We also demonstrated that the mother molecule, UDCA, is as efficacious in controlling the same parameters at equimolar doses. Moreover, our study demonstrates that NCX 1000 at lower doses can exert similar potent properties when combined with lipophilic antioxidants like vitamin E. On the other hand, we found that a 5-week treatment with silibinin, the major active component of milk thistle extract, improved liver steatosis and inflammation and decreased NASH-induced oxidative stress, insulin resistance, and fibrosis. These compounds have therefore the potential for being developed for the treatment of NASH. Clinical evidences are needed.

Cerebral ischaemia is a leading cause of disability and death world-wide. The only effective treatments are thrombolytic therapy (plasminogen activator; tPA) and hypothermia (33?C). However, tPA has limited clinical application due to its short therapeutic time window and its specific application in thrombo-embolic stroke. Moderate hypothermia (33?C) is only being used following cardiac arrest in comatose survivors. Hence more treatments are urgently required. The first step in developing new treatments is the identification and characterisation of a potential therapeutic target. Since brain damage following cerebral ischaemia is associated with disturbances in intracellular calcium homeostasis, the sodium-calcium exchanger (NCX) is a potential therapeutic target due to its ability to regulate intracellular calcium. Currently, however there is uncertainty as to whether the plasma membrane NCX has a neuroprotective or neurodamaging role following cerebral ischemia. To address this issue I compared hippocampal neuronal injury in NCX3 knockout mice (Ncx3-/-) and wild-type mice (Ncx3+/+) following global cerebral ischaemia. In order to perform this study I first established a bilateral common carotid occlusion (BCCAO) model of global ischaemia in wild-type C57/BlHsnD mice using controlled ventilation. After trials of several ischaemic time points, 17 minutes was established as the optimum duration of ischaemia to produce selective hippocampal CA1 neuronal loss in the wild-type mice. I then subjected NCX3 knockout and wild-type mice to 17 minutes of ischaemia. Following the 17 minute period of ischaemia, wild-type mice exhibited 80% CA1 neuronal loss and 40% CA2 neuronal loss. In contrast, NCX3 knockout mice displayed > 95% CA1 neuronal loss and 95% CA2 neuronal loss. Following experiments using a 17 minute duration of global ischaemia, a 15 minute duration of ischaemia was also evaluated. Wild-type mice exposed to a 15 minute period of ischaemia, did not exhibit any significant hippocampal neuronal loss. In contrast, NCX3 knockout mice displayed 45% CA1 neuronal loss and 25% CA2 neuronal loss. The results clearly demonstrate that mice deficient for the NCX3 protein are more susceptible to global cerebral ischaemia than wild-type mice. My findings showing a neuroprotective role for NCX3 following ischaemia, suggest that the exchanger has a positive role in maintaining neuronal intracellular calcium homeostasis. When this function is disrupted, neurons are more susceptible to calcium deregulation, with resultant cell death via calcium mediated pathways. Therefore, improving NCX activity following cerebral ischaemia may provide a therapeutic strategy to reduce neuronal death.

La stéatohépatite non alcoolique (NASH) est une pathologie du foie dont l’amplitude et les répercussions sont de plus en plus préoccupantes dans le monde médical ou biomédical. Elle est associée à l’obésité, au syndrome métabolique et au diabète sucré de type II. La recherche de la thérapie optimale pour le NASH est un domaine en plein essor puisqu’aucun traitement n’est suffisamment efficace à ce jour. La présente étude fait le point sur de nouvelles possibilités de traitements qui se sont avérés efficaces pour contrer les différentes lésions métaboliques et cellulaires rencontrées dans un modèle in vivo chez le rat où le NASH est induit par l’ingestion d’une diète riche en gras. Cette étude démontre, tout d’abord, que les traitements durant six semaines avec l’acide ursodéoxycholique (UDCA) et son dérivé le NCX 1000, possédant des propriétés donatrices de monoxyde d’azote, à doses équimolaires, protègent de manière équivalente le foie contre le stress oxydatif, l’hyperinsulinémie, l’inflammation et la fibrose causés par la stéatohépatite. De plus, la combinaison d’une plus faible dose de NCX 1000 avec un antioxydant lipophile tel que la vitamine E offre une protection similaire, particulièrement au niveau des paramètres du stress oxydatif. Par ailleurs, l’étude illustre aussi que la silibinine, composé polyphénolique actif du chardon marie (Silybum marianum) et utilisé en traitement pendant 5 semaines, possède un pouvoir hépatoprotecteur, des propriétés antioxydantes et un effet hypoinsulinémique dans ce modèle de stéatohépatite d’origine nutritionnelle. Le potentiel thérapeutique de ces composés en fait des candidats de choix pour le traitement du NASH qui méritent de faire l’objet d’études cliniques poussées. / Nonalcoholic steatohepatitis (NASH) is a serious liver condition related to the metabolic syndrome, obesity, and type II diabetes mellitus whose prevalence is drastically rising in developed countries and worldwide. Several remedies were investigated for the treatment of NASH but an efficient therapy has yet to be developed. In the present study, we explored novel therapeutic possibilities that were thought to be effective for the treatment of experimental high-fat diet-induced NASH the in rat. Our results show that a chronic six week treatment with a high dose of NCX 1000, a derivative of ursodeoxycholic acid (UDCA) with nitric oxide (NO) donating properties, is efficient at reversing steatosis, oxidative stress, inflammation, insulin resistance and fibrosis; major hallmarks of experimental NASH. We also demonstrated that the mother molecule, UDCA, is as efficacious in controlling the same parameters at equimolar doses. Moreover, our study demonstrates that NCX 1000 at lower doses can exert similar potent properties when combined with lipophilic antioxidants like vitamin E. On the other hand, we found that a 5-week treatment with silibinin, the major active component of milk thistle extract, improved liver steatosis and inflammation and decreased NASH-induced oxidative stress, insulin resistance, and fibrosis. These compounds have therefore the potential for being developed for the treatment of NASH. Clinical evidences are needed.

Made available in DSpace on 2016-06-02T19:22:12Z (GMT). No. of bitstreams: 1 6572.pdf: 3046018 bytes, checksum: a72ab59cf0526c45a9dee765c02c9f7c (MD5) Previous issue date: 2014-12-18 / Financiadora de Estudos e Projetos / The Sarcoplasmic reticulum calcium ATPase (SERCA), phospholamban (PLB) and the Na+-Ca2+ exchanger (NCX) proteins are essential for the cardiac calcium management and myocardial contractility in vertebrates. The increase in metabolic rate generated from mechanical and physiological process of digestion is known as specific dynamic action (SDA) and represents the energy cost of processing, digestion and absorption of food. In several groups of reptiles, feeding generates a rapid increase in rates of gas exchange, whose peak usually occurs one or two days after feeding, before suffering a slower decline and returning to preprandial values. Ingestion of large quantity of food demands a metabolic elevation and leads to indemnities related in ventricular mass and an increase in myocardial force contraction, avoiding an overload on the cardiovascular system. During the fasting, depletion of body mass occurs and it can also reach the heart muscle. To describe the importance and the changes in SERCA2, PLB and NCX proteins on the effects of feeding/digestion in reptiles broad-snouted caiman (Caiman latirostris), burmese phyton (Python molurus) and also by prolonged fasting in South-American rattlesnake (Crotalus durissus terrificus) Western blotting technique was used. We observed the homology existence between the proteins of reptiles in relation to mammals. The SDA increased expression of SERCA2 protein in three species of reptiles. The SDA can also have unduced the expression of an isoform and/or reduced phosphorylation at some active sites of SERCA2 in ventricular tissue of P. molurus. A direct relationship between the expression of SERCA2 with the PLB expression in C. durissus was observed. However in P. molurus and C. latirostris this relation does not exist. The three reptiles expressed the PLB with molecular mass of 50 kDa, whereas the mouse expressed 25 kDa. The vast evolutionary distance that separates mammals of reptiles may have caused the rise of isoforms between these groups, explaining this difference. The increased expression of NCX along with lower expression of SERCA2 and PLB in C. durissus in food group Fasting compared to the other two groups suggests a higher calcium mobilization in this feeding regime, which would be advantageous from the energy point of view. The expression of NCX with different molecular mass between the three species, a smaller number of consensus regions with the animals phylogenetically more distant and the great plasticity of NCX gene to form distinct proteins, suggest the expression of proteins isoforms with the reptiles studied in this research. / As proteínas Ca2+-ATPase do Retículo Sarcoplasmático (SERCA2), Fosfolambam (PLB) e o Trocador Na+/Ca2+ (NCX) são fundamentais para o manejo do cálcio e a contratilidade miocárdica nos vertebrados. A elevação da taxa metabólica gerada a partir dos processos mecânicos e fisiológicos da digestão é conhecida como "ação dinâmica específica" (SDA) e representa o custo energético do processamento, digestão e absorção dos alimentos. Em vários grupos de répteis, a alimentação gera um rápido aumento nas taxas de troca gasosa, cujo pico ocorre geralmente um dia ou dois após a alimentação, antes de sofrer um declínio mais lento e retornar aos valores pré-prandiais. A ingestão de grandes massas de alimento demanda uma elevação metabólica e leva a uma compensação na massa ventricular e um aumento na força de contração do miocárdio, evitando uma sobrecarga no sistema cardiovascular. Durante o jejum ocorre depleção da estrutura corpórea podendo também atingir o músculo cardíaco. Para descrever a importância e as mudanças nas proteínas SERCA2, PLB e NCX diante os efeitos da alimentação/digestão nos répteis cascavel sul-americana (Crotalus durissus terrificus), na píton (Python molurus) e também do jejum prolongado no jacaré-de-papo-amarelo (Caiman latirostris), utilizada a técnica molecular Western blotting. Observou-se a existência de homologia entre as proteínas dos répteis com relação aos mamíferos. A SDA levou a uma maior expressão da proteína SERCA2 nas três espécies de répteis. A SDA também pode ter induzido a expressão de uma isoforma e/ou uma menor fosforilação em alguns sítios ativos da SERCA2 no tecido ventricular de P. molurus. Uma relação direta entre a expressão da SERCA2 com a expressão do PLB foi verificada somente em C. durissus, não havendo tal relação em P. molurus e C. latirostris. As três espécies de répteis expressaram o PLB com mesma massa molecular, de 50 kDa, e diferente da do rato, que é de 25 kDa. A grande distância evolutiva que separa os répteis dos mamíferos pode ter ocasionado o surgimento de isoformas entre esses grupos, explicando tal diferença. O aumento da expressão do NCX em C. latirostris do grupo alimentar Digestão sugere uma maior mobilização do cálcio e um maior inotropismo de forma frequência-específica através dessa proteína. A maior expressão do NCX juntamente com a menor expressão da SERCA2 e do PLB em C. durissus no grupo alimentar Jejum em relação aos outros dois grupos alimentares sugere uma maior mobilização do cálcio pelo NCX nesse regime de alimentação, o que seria vantajoso do ponto de vista energético. A expressão do NCX com diferentes massas moleculares entre as três espécies estudadas, um menor número de regiões conservadas em animais filogeneticamente mais distantes, e a grande plasticidade do gene da proteína NCX em formar proteínas distintas, sugere a expressão de proteínas isoformas nos répteis estudados.

No description available.